Follow up study during and after two month regimen of Benznidazole in pediatric chronic Chagas patients in Bolivia

Simple item page
dc.contributor.authorClara Vásquez Velásquez
dc.contributor.authorEmilio E. Espínola
dc.contributor.authorZunilda Sánchez
dc.contributor.authorKota Mochizuki
dc.contributor.authorJimmy Revollo
dc.contributor.authorAngelica Guzman
dc.contributor.authorBenjamín Quiroga
dc.contributor.authorJuan Eiki Nishizawa
dc.contributor.authorGraciela Russomando
dc.contributor.authorKenji Hirayama
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T18:13:50Z
dc.date.available2026-03-22T18:13:50Z
dc.date.issued2018
dc.description.abstractIntroduction: Chagas disease is a parasitic infection endemic in Latin America caused by Trypanosoma cruzi. In Bolivia, vector control activity by the National Program for Chagas has greatly decreased the number of natural infections since 2006. The program began a treatment regimen of Benznidazole (BNZ) (5mg/kg/day) for 2 months in seropositive children aged 4-15 years living in certified vector controlled areas.
dc.identifier.doi10.1254/jpssuppl.wcp2018.0_po2-11-18
dc.identifier.urihttps://doi.org/10.1254/jpssuppl.wcp2018.0_po2-11-18
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/68881
dc.language.isoen
dc.publisherJapanese Pharmacological Society
dc.relation.ispartofProceedings for Annual Meeting of The Japanese Pharmacological Society
dc.sourceNagasaki University
dc.subjectBenznidazole
dc.subjectChagas disease
dc.subjectRegimen
dc.subjectTrypanosoma cruzi
dc.subjectMedicine
dc.subjectVector (molecular biology)
dc.subjectInternal medicine
dc.titleFollow up study during and after two month regimen of Benznidazole in pediatric chronic Chagas patients in Bolivia
dc.typearticle

Files

Collections

Artículo Científico Publicado